GNAS-related pituitary adenoma 3

Neoplastic Pathograph 9 pituitary gland adenoma

GNAS-related pituitary adenoma 3 represents growth hormone-secreting pituitary tumors driven by somatic activating GNAS mutations. Mechanistically, GNAS is more similar to GPR101 than to AIP: it enters the shared somatotroph cAMP/PKA module by constitutive Gs-alpha activation and increased adenylyl cyclase/cAMP activity rather than by biallelic tumor-suppressor loss.

Ask OpenScientist

Ask a research question about GNAS-related pituitary adenoma 3. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
5
Pathophys.
3
Phenotypes
2
Gaps
9
Pathograph
1
Genes
2
Medical Actions
6
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0006373 pituitary gland adenoma Not Yet Curated
skos:closeMatch MONDO
Closest available MONDO grouping term for somatic GNAS-driven pituitary adenoma; a gene-specific PITA3 term is not represented in the local ontology snapshot.
?

Discussions and Knowledge Gaps

2
How should McCune-Albright syndrome be distinguished from sporadic GNAS-mutant somatotroph tumors?
INTERPRETATION OPEN context_gnas_mccune_albright_mosaicism
Attached to
pathophysiology#Somatic activating GNAS mutation
This entry models GNAS-related pituitary adenoma primarily as a sporadic tumor-somatic hotspot mechanism. McCune-Albright syndrome is related biology because it is also caused by somatic activating GNAS mutations and can include growth hormone excess, but it is a broader mosaic multisystem disorder rather than the usual isolated somatotroph tumor context.
Show evidence (3 references)
PMID:31673695 SUPPORT Other
"It arises from somatic, gain-of-function mutations in GNAS"
This supports the somatic gain-of-function GNAS basis of McCune-Albright/fibrous dysplasia syndrome.
PMID:31673695 SUPPORT Other
"This review presents FD/MAS in the context of a mosaic disorder"
This supports distinguishing the FD/MAS setting as mosaic rather than a typical isolated sporadic tumor.
PMID:18489744 SUPPORT Other
"other hyperfunctioning endocrinopathies may be involved including hyperthyroidism, growth hormone excess, Cushing syndrome, and renal phosphate wasting."
This supports growth hormone excess as a possible endocrine manifestation in McCune-Albright syndrome.
Does somatic GNAS/gsp status predict somatostatin receptor ligand response in clinically useful subsets of acromegaly?
KNOWLEDGE GAP OPEN gap_gnas_srl_response_prediction
Attached to
pathophysiology#Somatic activating GNAS mutation treatment#First-generation somatostatin receptor ligand therapy
GNAS activates the cAMP/PKA somatotroph module, but the largest available series did not support gsp status as a long-term first-generation SRL response biomarker. Treatment response should therefore remain an outcome association rather than a hard mechanistic edge.
Show evidence (1 reference)
PMID:34638340 SUPPORT Human Clinical
"In this largest series available in the literature, we concluded that gsp is not a molecular biomarker of response to fg-SRL treatment in acromegaly."
This motivates retaining GNAS/SRL response prediction as a knowledge gap.
⚙

Pathophysiology

5
Somatic activating GNAS mutation
A somatic GNAS missense mutation inhibits intrinsic GTPase activity of Gs-alpha, stabilizing the protein in its active conformation.
GNAS hgnc:4392 ↑ INCREASED
Genetic context GNAS hgnc:4392 variant_origin: SOMATIC allelic_event: MISSENSE_VARIANT functional_impact_category: GAIN_OF_FUNCTION
Somatic GNAS substitutions at residues such as Arg-201 or Gln-227 inhibit GTP hydrolysis and keep Gs-alpha active.
GNAS intrinsic GTPase activity GO:0003924 ↓ DECREASED
pituitary gland UBERON:0000007
Downstream
Constitutive Gs-alpha adenylate cyclase activation Active Gs-alpha stimulates adenylyl cyclase and increases cAMP production.
Show evidence (1 reference)
PMID:2124121 SUPPORT Human Clinical
"By substitution of a single amino acid (Arg-201 or Gln-227), these mutations inhibit the intrinsic GTPase activity of alpha s, thus stabilizing the protein in its active conformation."
This directly supports the proximal biochemical effect of the activating GNAS mutations.
Constitutive Gs-alpha adenylate cyclase activation
Active Gs-alpha increases adenylyl cyclase activity and intracellular cAMP levels in GH-secreting pituitary tumor cells.
somatotroph CL:0002312
GNAS hgnc:4392 ↑ INCREASED
cAMP biosynthetic process GO:0006171 ↑ INCREASED
adenylate cyclase activator activity GO:0010856 ↑ INCREASED
Downstream
Increased cAMP/PKA signaling in somatotrophs Increased cAMP availability activates the shared somatotroph cAMP/PKA module.
Show evidence (1 reference)
PMID:2124121 SUPPORT Human Clinical
"A subset of human growth hormone (GH)-secreting pituitary tumours, characterized by elevated GH secretion, cyclic AMP levels, and adenylyl cyclase activity, carries mutations in the gene that encodes the alpha-chain of Gs."
This supports increased adenylyl cyclase and cAMP as the biochemical state downstream of GNAS mutation.
Increased cAMP/PKA signaling in somatotrophs
GNAS-mutant somatotroph tumors converge on the same cAMP/PKA signaling cassette reached by GPR101 activation and by AIP loss through reduced cAMP-degrading restraint.
somatotroph CL:0002312
cAMP/PKA signal transduction GO:0141156 ↑ INCREASED
Downstream
Increased growth hormone secretion cAMP/PKA signaling drives excess GH secretion.
Somatotroph adenoma growth cAMP-responsive somatotroph cells proliferate in the presence of oncogenic Gs-alpha signaling.
Show evidence (1 reference)
PMID:2124121 SUPPORT Human Clinical
"A subset of human growth hormone (GH)-secreting pituitary tumours, characterized by elevated GH secretion, cyclic AMP levels, and adenylyl cyclase activity, carries mutations in the gene that encodes the alpha-chain of Gs."
This supports cAMP pathway activation in GNAS-mutant GH-secreting tumors.
Increased growth hormone secretion
GNAS-mutant GH-secreting pituitary tumors show elevated growth hormone secretion downstream of cAMP pathway activation.
somatotroph CL:0002312
growth hormone secretion GO:0030252 ↑ INCREASED
Show evidence (1 reference)
PMID:2124121 SUPPORT Human Clinical
"A subset of human growth hormone (GH)-secreting pituitary tumours, characterized by elevated GH secretion, cyclic AMP levels, and adenylyl cyclase activity, carries mutations in the gene that encodes the alpha-chain of Gs."
This directly links GNAS-mutant pituitary tumors with elevated GH secretion.
Somatotroph adenoma growth
Activating GNAS turns Gs-alpha into an oncogenic driver in somatotroph cells that proliferate in response to cAMP.
somatotroph CL:0002312
cell population proliferation GO:0008283 ↑ INCREASED
pituitary gland UBERON:0000007
Show evidence (1 reference)
PMID:2124121 SUPPORT Human Clinical
"The discovery of mutant alpha s proteins in human tumours suggests that the alpha s gene can be converted into an oncogene, called gsp, in cells that proliferate in response to cyclic AMP."
This supports the proliferative tumor context for activating GNAS in cAMP-responsive pituitary cells.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for GNAS-related pituitary adenoma 3 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

3
Growth hormone excess HP:0000845
Show evidence (1 reference)
PMID:2124121 SUPPORT Human Clinical
"A subset of human growth hormone (GH)-secreting pituitary tumours, characterized by elevated GH secretion, cyclic AMP levels, and adenylyl cyclase activity, carries mutations in the gene that encodes the alpha-chain of Gs."
This supports GH excess as the hormone output of GNAS-mutant pituitary tumors.
Pituitary adenoma HP:0002893
Show evidence (1 reference)
PMID:2124121 SUPPORT Human Clinical
"A subset of human growth hormone (GH)-secreting pituitary tumours, characterized by elevated GH secretion, cyclic AMP levels, and adenylyl cyclase activity, carries mutations in the gene that encodes the alpha-chain of Gs."
The cited human tumors are pituitary tumors, supporting pituitary adenoma as the structural disease outcome.
Acral overgrowth HP:0033794
Show evidence (1 reference)
PMID:27812777 SUPPORT Human Clinical
"Excessive growth of hands and feet (predominantly due to soft tissue swelling) is present in the vast majority of acromegalic patients."
This directly supports acral overgrowth as the characteristic clinical overgrowth phenotype downstream of GH/IGF-1 excess.
🧬

Genetic Associations

1
GNAS (Somatic activating GNAS mutations act as gsp oncogenic drivers in a subset of growth hormone-secreting pituitary tumors.)
Gene: GNAS hgnc:4392 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:2124121 SUPPORT Human Clinical
"A subset of human growth hormone (GH)-secreting pituitary tumours, characterized by elevated GH secretion, cyclic AMP levels, and adenylyl cyclase activity, carries mutations in the gene that encodes the alpha-chain of Gs."
This identifies GNAS mutation as the driver alteration in a subset of GH-secreting pituitary tumors.
💊

Medical Actions

2
Multimodal acromegaly therapy
Action: therapeutic procedure Ontology label: Therapeutic Procedure NCIT:C49236
GNAS-mutant acromegaly is managed within standard acromegaly algorithms using biochemical monitoring and combinations of surgery, medical therapy, and radiotherapy as clinically indicated.
Mechanism Target:
MODULATES Increased growth hormone secretion — Multimodal treatment aims to reduce GH/IGF-1 excess and tumor burden downstream of GNAS-driven cAMP/PKA activation.
Target Phenotypes: Growth hormone excess HP:0000845
Show evidence (1 reference)
PMID:25356808 SUPPORT Other
"including the appropriate biochemical assessment, a therapeutic algorithm, including use of medical monotherapy or combination therapy, and management during pregnancy."
This guideline summary supports multimodal therapeutic management for acromegaly.
First-generation somatostatin receptor ligand therapy
Action: pharmacotherapy MAXO:0000058
First-generation somatostatin receptor ligands are used to control GH/IGF-1 excess in acromegaly, but gsp/GNAS mutation status should not be modeled as a reliable predictor of long-term response.
Mechanism Target:
MODULATES Increased growth hormone secretion — Somatostatin receptor ligands suppress GH secretion downstream of the GNAS-driven somatotroph state, but response is not determined by GNAS status alone.
Target Phenotypes: Growth hormone excess HP:0000845
Show evidence (2 references)
PMID:34638340 SUPPORT Human Clinical
"Biochemical control with fg-SRL treatment was similar in gsp+ and gsp- patients (37% vs. 25%, p = 0.219)."
This supports adding SRL therapy while explicitly avoiding an overstrong GNAS-positive response claim.
PMID:34638340 SUPPORT Human Clinical
"gsp is not a molecular biomarker of response to fg-SRL treatment in acromegaly."
This supports modeling GNAS/SRL response as uncertain rather than a deterministic mechanism.
{ }

Source YAML

click to show 
name: GNAS-related pituitary adenoma 3
creation_date: "2026-06-03T00:00:00Z"
category: Neoplastic
categories:
- Endocrine Neoplasia
- Somatic Mosaicism
parents:
- pituitary gland adenoma
disease_term:
  preferred_term: GNAS-related pituitary adenoma 3
synonyms:
- Pituitary adenoma 3
- gsp-positive somatotroph adenoma
- GNAS-mutant growth hormone-secreting pituitary tumor
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0006373
      label: pituitary gland adenoma
    mapping_predicate: skos:closeMatch
    mapping_source: MONDO
    mapping_justification: >-
      Closest available MONDO grouping term for somatic GNAS-driven pituitary
      adenoma; a gene-specific PITA3 term is not represented in the local
      ontology snapshot.
description: >-
  GNAS-related pituitary adenoma 3 represents growth hormone-secreting
  pituitary tumors driven by somatic activating GNAS mutations. Mechanistically,
  GNAS is more similar to GPR101 than to AIP: it enters the shared somatotroph
  cAMP/PKA module by constitutive Gs-alpha activation and increased adenylyl
  cyclase/cAMP activity rather than by biallelic tumor-suppressor loss.
references:
- reference: PMID:2124121
  title: "GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours."
  findings:
  - statement: >-
      GH-secreting pituitary tumors can carry GNAS mutations that inhibit
      intrinsic GTPase activity, stabilize Gs-alpha in an active conformation,
      and associate with elevated GH secretion, cAMP, and adenylyl cyclase
      activity.
- reference: PMID:25356808
  title: "Acromegaly: an endocrine society clinical practice guideline."
  findings:
  - statement: >-
      Acromegaly management uses biochemical assessment and multimodal therapy,
      including medical monotherapy or combination therapy.
- reference: PMID:27812777
  title: "Acromegaly: clinical features at diagnosis."
  findings:
  - statement: >-
      Acromegaly produces somatic overgrowth and typical facial and acral
      overgrowth phenotypes downstream of GH/IGF-1 excess.
- reference: PMID:34638340
  title: "gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly."
  findings:
  - statement: >-
      In a 136-patient series, gsp/GNAS status was not a reliable biomarker of
      long-term first-generation somatostatin receptor ligand response.
- reference: PMID:31673695
  title: "Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation."
  findings:
  - statement: >-
      McCune-Albright syndrome/fibrous dysplasia is a somatic mosaic
      gain-of-function GNAS disorder, distinct from the usual sporadic
      tumor-somatic GNAS context modeled here.
- reference: PMID:18489744
  title: "McCune-Albright syndrome."
  findings:
  - statement: >-
      McCune-Albright syndrome can include growth hormone excess among its
      hyperfunctioning endocrinopathies.
genetic:
- name: GNAS
  gene_term:
    preferred_term: GNAS
    term:
      id: hgnc:4392
      label: GNAS
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  association: >-
    Somatic activating GNAS mutations act as gsp oncogenic drivers in a subset
    of growth hormone-secreting pituitary tumors.
  evidence:
  - reference: PMID:2124121
    reference_title: "GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A subset of human growth hormone (GH)-secreting pituitary tumours,
      characterized by elevated GH secretion, cyclic AMP levels, and adenylyl
      cyclase activity, carries mutations in the gene that encodes the
      alpha-chain of Gs.
    explanation: >-
      This identifies GNAS mutation as the driver alteration in a subset of
      GH-secreting pituitary tumors.
pathophysiology:
- name: Somatic activating GNAS mutation
  description: >-
    A somatic GNAS missense mutation inhibits intrinsic GTPase activity of
    Gs-alpha, stabilizing the protein in its active conformation.
  role: trigger
  gene:
    preferred_term: GNAS
    modifier: INCREASED
    term:
      id: hgnc:4392
      label: GNAS
  genetic_context:
    gene:
      preferred_term: GNAS
      term:
        id: hgnc:4392
        label: GNAS
    variant_origin: SOMATIC
    allelic_events:
    - MISSENSE_VARIANT
    functional_impact_category: GAIN_OF_FUNCTION
    description: >-
      Somatic GNAS substitutions at residues such as Arg-201 or Gln-227 inhibit
      GTP hydrolysis and keep Gs-alpha active.
  molecular_functions:
  - preferred_term: GNAS intrinsic GTPase activity
    modifier: DECREASED
    term:
      id: GO:0003924
      label: GTPase activity
  locations:
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  evidence:
  - reference: PMID:2124121
    reference_title: "GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      By substitution of a single amino acid (Arg-201 or Gln-227), these
      mutations inhibit the intrinsic GTPase activity of alpha s, thus
      stabilizing the protein in its active conformation.
    explanation: >-
      This directly supports the proximal biochemical effect of the activating
      GNAS mutations.
  downstream:
  - target: Constitutive Gs-alpha adenylate cyclase activation
    description: >-
      Active Gs-alpha stimulates adenylyl cyclase and increases cAMP production.
    causal_link_type: DIRECT

- name: Constitutive Gs-alpha adenylate cyclase activation
  description: >-
    Active Gs-alpha increases adenylyl cyclase activity and intracellular cAMP
    levels in GH-secreting pituitary tumor cells.
  role: upstream_effector
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  gene:
    preferred_term: GNAS
    modifier: INCREASED
    term:
      id: hgnc:4392
      label: GNAS
  molecular_functions:
  - preferred_term: adenylate cyclase activator activity
    modifier: INCREASED
    term:
      id: GO:0010856
      label: adenylate cyclase activator activity
  biological_processes:
  - preferred_term: cAMP biosynthetic process
    modifier: INCREASED
    term:
      id: GO:0006171
      label: cAMP biosynthetic process
  evidence:
  - reference: PMID:2124121
    reference_title: "GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A subset of human growth hormone (GH)-secreting pituitary tumours,
      characterized by elevated GH secretion, cyclic AMP levels, and adenylyl
      cyclase activity, carries mutations in the gene that encodes the
      alpha-chain of Gs.
    explanation: >-
      This supports increased adenylyl cyclase and cAMP as the biochemical
      state downstream of GNAS mutation.
  downstream:
  - target: Increased cAMP/PKA signaling in somatotrophs
    description: >-
      Increased cAMP availability activates the shared somatotroph cAMP/PKA
      module.
    causal_link_type: DIRECT

- name: Increased cAMP/PKA signaling in somatotrophs
  conforms_to: somatotroph_camp_pka_overactivation#Increased cAMP/PKA signaling in somatotrophs
  description: >-
    GNAS-mutant somatotroph tumors converge on the same cAMP/PKA signaling
    cassette reached by GPR101 activation and by AIP loss through reduced
    cAMP-degrading restraint.
  role: central_effector
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  biological_processes:
  - preferred_term: cAMP/PKA signal transduction
    modifier: INCREASED
    term:
      id: GO:0141156
      label: cAMP/PKA signal transduction
  evidence:
  - reference: PMID:2124121
    reference_title: "GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A subset of human growth hormone (GH)-secreting pituitary tumours,
      characterized by elevated GH secretion, cyclic AMP levels, and adenylyl
      cyclase activity, carries mutations in the gene that encodes the
      alpha-chain of Gs.
    explanation: >-
      This supports cAMP pathway activation in GNAS-mutant GH-secreting tumors.
  downstream:
  - target: Increased growth hormone secretion
    description: >-
      cAMP/PKA signaling drives excess GH secretion.
    causal_link_type: DIRECT
  - target: Somatotroph adenoma growth
    description: >-
      cAMP-responsive somatotroph cells proliferate in the presence of
      oncogenic Gs-alpha signaling.
    causal_link_type: DIRECT

- name: Increased growth hormone secretion
  conforms_to: somatotroph_camp_pka_overactivation#Increased growth hormone secretion
  description: >-
    GNAS-mutant GH-secreting pituitary tumors show elevated growth hormone
    secretion downstream of cAMP pathway activation.
  role: consequence
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  biological_processes:
  - preferred_term: growth hormone secretion
    modifier: INCREASED
    term:
      id: GO:0030252
      label: growth hormone secretion
  evidence:
  - reference: PMID:2124121
    reference_title: "GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A subset of human growth hormone (GH)-secreting pituitary tumours,
      characterized by elevated GH secretion, cyclic AMP levels, and adenylyl
      cyclase activity, carries mutations in the gene that encodes the
      alpha-chain of Gs.
    explanation: >-
      This directly links GNAS-mutant pituitary tumors with elevated GH
      secretion.

- name: Somatotroph adenoma growth
  conforms_to: somatotroph_camp_pka_overactivation#Somatotroph proliferation and adenoma growth
  description: >-
    Activating GNAS turns Gs-alpha into an oncogenic driver in somatotroph cells
    that proliferate in response to cAMP.
  role: consequence
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  locations:
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:2124121
    reference_title: "GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The discovery of mutant alpha s proteins in human tumours suggests that
      the alpha s gene can be converted into an oncogene, called gsp, in cells
      that proliferate in response to cyclic AMP.
    explanation: >-
      This supports the proliferative tumor context for activating GNAS in
      cAMP-responsive pituitary cells.
phenotypes:
- name: Growth hormone excess
  phenotype_term:
    preferred_term: Elevated circulating growth hormone concentration
    term:
      id: HP:0000845
      label: Elevated circulating growth hormone concentration
  evidence:
  - reference: PMID:2124121
    reference_title: "GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A subset of human growth hormone (GH)-secreting pituitary tumours,
      characterized by elevated GH secretion, cyclic AMP levels, and adenylyl
      cyclase activity, carries mutations in the gene that encodes the
      alpha-chain of Gs.
    explanation: >-
      This supports GH excess as the hormone output of GNAS-mutant pituitary
      tumors.
- name: Pituitary adenoma
  phenotype_term:
    preferred_term: Pituitary adenoma
    term:
      id: HP:0002893
      label: Pituitary adenoma
  evidence:
  - reference: PMID:2124121
    reference_title: "GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A subset of human growth hormone (GH)-secreting pituitary tumours,
      characterized by elevated GH secretion, cyclic AMP levels, and adenylyl
      cyclase activity, carries mutations in the gene that encodes the
      alpha-chain of Gs.
    explanation: >-
      The cited human tumors are pituitary tumors, supporting pituitary adenoma
      as the structural disease outcome.
- name: Acral overgrowth
  phenotype_term:
    preferred_term: Acral overgrowth
    term:
      id: HP:0033794
      label: Acral overgrowth
  evidence:
  - reference: PMID:27812777
    reference_title: "Acromegaly: clinical features at diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Excessive growth of hands and feet (predominantly due to soft tissue
      swelling) is present in the vast majority of acromegalic patients.
    explanation: >-
      This directly supports acral overgrowth as the characteristic clinical
      overgrowth phenotype downstream of GH/IGF-1 excess.
diagnosis:
- name: Biochemical assessment of acromegaly
  diagnosis_term:
    preferred_term: hormone measurement
    term:
      id: MAXO:0035058
      label: hormone measurement
  description: >-
    GH and IGF-1 biochemical assessment establishes and monitors the acromegaly
    phenotype produced by GNAS-mutant somatotroph tumors.
  results: >-
    Elevated GH and IGF-1 support active acromegaly; normalization is used to
    assess treatment response.
  evidence:
  - reference: PMID:25356808
    reference_title: "Acromegaly: an endocrine society clinical practice guideline."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      including the appropriate biochemical assessment, a therapeutic algorithm,
      including use of medical monotherapy or combination therapy, and
      management during pregnancy.
    explanation: >-
      The guideline abstract supports biochemical assessment as part of
      acromegaly evaluation and management.
- name: Somatotroph tumor GNAS sequencing
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
    qualifiers:
    - predicate:
        preferred_term: has participant
        term:
          id: RO:0000057
          label: has participant
      value:
        preferred_term: GNAS
        term:
          id: hgnc:4392
          label: GNAS
  description: >-
    Tumor sequencing can identify somatic GNAS/gsp mutations in resected
    somatotroph adenomas.
  results: >-
    Identification of a somatic activating GNAS mutation classifies the tumor as
    gsp-positive.
  evidence:
  - reference: PMID:34638340
    reference_title: "gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GNAS1 sequencing was performed by Sanger.
    explanation: >-
      This supports molecular tumor testing for GNAS/gsp status in acromegaly
      cohorts.
treatments:
- name: Multimodal acromegaly therapy
  description: >-
    GNAS-mutant acromegaly is managed within standard acromegaly algorithms
    using biochemical monitoring and combinations of surgery, medical therapy,
    and radiotherapy as clinically indicated.
  treatment_term:
    preferred_term: therapeutic procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_phenotypes:
  - preferred_term: Growth hormone excess
    term:
      id: HP:0000845
      label: Elevated circulating growth hormone concentration
  target_mechanisms:
  - target: Increased growth hormone secretion
    treatment_effect: MODULATES
    description: >-
      Multimodal treatment aims to reduce GH/IGF-1 excess and tumor burden
      downstream of GNAS-driven cAMP/PKA activation.
  evidence:
  - reference: PMID:25356808
    reference_title: "Acromegaly: an endocrine society clinical practice guideline."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      including the appropriate biochemical assessment, a therapeutic algorithm,
      including use of medical monotherapy or combination therapy, and
      management during pregnancy.
    explanation: >-
      This guideline summary supports multimodal therapeutic management for
      acromegaly.
- name: First-generation somatostatin receptor ligand therapy
  description: >-
    First-generation somatostatin receptor ligands are used to control GH/IGF-1
    excess in acromegaly, but gsp/GNAS mutation status should not be modeled as
    a reliable predictor of long-term response.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  target_phenotypes:
  - preferred_term: Growth hormone excess
    term:
      id: HP:0000845
      label: Elevated circulating growth hormone concentration
  target_mechanisms:
  - target: Increased growth hormone secretion
    treatment_effect: MODULATES
    description: >-
      Somatostatin receptor ligands suppress GH secretion downstream of the
      GNAS-driven somatotroph state, but response is not determined by GNAS
      status alone.
  evidence:
  - reference: PMID:34638340
    reference_title: "gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Biochemical control with fg-SRL treatment was similar in gsp+ and gsp-
      patients (37% vs. 25%, p = 0.219).
    explanation: >-
      This supports adding SRL therapy while explicitly avoiding an overstrong
      GNAS-positive response claim.
  - reference: PMID:34638340
    reference_title: "gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      gsp is not a molecular biomarker of response to fg-SRL treatment in
      acromegaly.
    explanation: >-
      This supports modeling GNAS/SRL response as uncertain rather than a
      deterministic mechanism.
discussions:
- discussion_id: context_gnas_mccune_albright_mosaicism
  prompt: >-
    How should McCune-Albright syndrome be distinguished from sporadic
    GNAS-mutant somatotroph tumors?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - pathophysiology#Somatic activating GNAS mutation
  rationale: >-
    This entry models GNAS-related pituitary adenoma primarily as a sporadic
    tumor-somatic hotspot mechanism. McCune-Albright syndrome is related
    biology because it is also caused by somatic activating GNAS mutations and
    can include growth hormone excess, but it is a broader mosaic multisystem
    disorder rather than the usual isolated somatotroph tumor context.
  evidence:
  - reference: PMID:31673695
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      It arises from somatic, gain-of-function mutations in GNAS
    explanation: >-
      This supports the somatic gain-of-function GNAS basis of
      McCune-Albright/fibrous dysplasia syndrome.
  - reference: PMID:31673695
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This review presents FD/MAS in the context of a mosaic disorder
    explanation: >-
      This supports distinguishing the FD/MAS setting as mosaic rather than a
      typical isolated sporadic tumor.
  - reference: PMID:18489744
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      other hyperfunctioning endocrinopathies may be involved including
      hyperthyroidism, growth hormone excess, Cushing syndrome, and renal
      phosphate wasting.
    explanation: >-
      This supports growth hormone excess as a possible endocrine manifestation
      in McCune-Albright syndrome.
- discussion_id: gap_gnas_srl_response_prediction
  prompt: >-
    Does somatic GNAS/gsp status predict somatostatin receptor ligand response
    in clinically useful subsets of acromegaly?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Somatic activating GNAS mutation
  - treatment#First-generation somatostatin receptor ligand therapy
  rationale: >-
    GNAS activates the cAMP/PKA somatotroph module, but the largest available
    series did not support gsp status as a long-term first-generation SRL
    response biomarker. Treatment response should therefore remain an outcome
    association rather than a hard mechanistic edge.
  evidence:
  - reference: PMID:34638340
    reference_title: "gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this largest series available in the literature, we concluded that gsp
      is not a molecular biomarker of response to fg-SRL treatment in
      acromegaly.
    explanation: >-
      This motivates retaining GNAS/SRL response prediction as a knowledge gap.
📚

References & Deep Research

References

6
PMID:2124121
GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours.
1 finding
GH-secreting pituitary tumors can carry GNAS mutations that inhibit intrinsic GTPase activity, stabilize Gs-alpha in an active conformation, and associate with elevated GH secretion, cAMP, and adenylyl cyclase activity.
PMID:25356808
Acromegaly: an endocrine society clinical practice guideline.
1 finding
Acromegaly management uses biochemical assessment and multimodal therapy, including medical monotherapy or combination therapy.
PMID:27812777
Acromegaly: clinical features at diagnosis.
1 finding
Acromegaly produces somatic overgrowth and typical facial and acral overgrowth phenotypes downstream of GH/IGF-1 excess.
PMID:34638340
gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
1 finding
In a 136-patient series, gsp/GNAS status was not a reliable biomarker of long-term first-generation somatostatin receptor ligand response.
PMID:31673695
Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.
1 finding
McCune-Albright syndrome/fibrous dysplasia is a somatic mosaic gain-of-function GNAS disorder, distinct from the usual sporadic tumor-somatic GNAS context modeled here.
PMID:18489744
McCune-Albright syndrome.
1 finding
McCune-Albright syndrome can include growth hormone excess among its hyperfunctioning endocrinopathies.

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 23 citations 2026-06-03T16:03:26.216440

1. Disease Information

1.1 Definition / overview

Pituitary neuroendocrine tumors (PitNETs; historically “pituitary adenomas”) are common intracranial neoplasms; clinically relevant pituitary adenomas occur at an estimated prevalence of ~1 in 1000. (torresmoran2023hotspotsofsomatic pages 1-2)

In this context, GNAS-related pituitary adenomas most commonly refer to growth hormone (GH)-secreting somatotroph PitNETs (and often mammosomatotroph tumors with GH±prolactin co-secretion) that cause acromegaly and harbor somatic activating hotspot mutations in GNAS (also referred to historically as the gsp oncogene). (dillon2026clinicalcharacteristicsassociated pages 1-2, vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic pages 1-2)

Direct abstract support (review): Sousa et al. (2023) states: “The vast majority of pituitary tumours are pituitary adenomas, also recently referred to as pituitary neuroendocrine tumours (PitNET)… In addition, we discuss McCune-Albright syndrome… [where] causative GNAS mutations are postzygotic…” and contrasts this with “somatic GNAS mutations [that] contribute to sporadic acromegaly.” (torresmoran2023hotspotsofsomatic pages 1-2)

1.2 Key identifiers (and gaps)

  • MONDO / OMIM / Orphanet / MeSH / ICD-10/11: A specific identifier for the exact phrase “GNAS-related pituitary adenoma 3” was not found in the retrieved evidence set.
  • Best practical mapping using retrieved disease ontologies: Open Targets disease associations link GNAS to:
  • “Pituitary Gland Adenoma” (EFO_1000478)
  • “Growth Hormone-Producing Pituitary Gland Adenoma” (EFO_1000287)
  • “Mixed Somatotroph-Lactotroph Pituitary Gland Adenoma” (EFO_1000383) supporting that this entity corresponds to GH-lineage PitNETs. (OpenTargets Search: pituitary adenoma,acromegaly-GNAS)

1.3 Synonyms / alternative names

  • Pituitary adenoma (historical)
  • Pituitary neuroendocrine tumor (PitNET) (current WHO-aligned terminology in much of recent literature) (torresmoran2023hotspotsofsomatic pages 1-2)
  • Somatotroph PitNET / somatotropinoma / GH-secreting pituitary adenoma (rymuza2024highlevelof pages 1-2)
  • Mammosomatotroph adenoma/PitNET (GH+PRL) (dillon2026clinicalcharacteristicsassociated pages 1-2)
  • “gsp” oncogene-positive somatotroph tumor (historical term for GNAS-activating variants) (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8)

1.4 Evidence source type for disease information

The disease characterization here is derived from aggregated disease-level resources and cohort/review literature, not individual EHR-derived entities. (OpenTargets Search: pituitary adenoma,acromegaly-GNAS, dillon2026clinicalcharacteristicsassociated pages 1-2, vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary causal factor (molecular): Somatic gain-of-function GNAS variants (hotspots at residues R201 and Q227) cause constitutive Gsα activation, driving cAMP/PKA signaling in somatotroph-lineage pituitary cells and contributing to tumorigenesis and GH hypersecretion. (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic media 804a8a89, torresmoran2023hotspotsofsomatic media 493c647d)

2.2 Risk factors

  • Genetic (somatic) risk factor: Presence of tumor somatic GNAS hotspot mutations in somatotroph PitNETs; cohort-level prevalence is commonly ~30–40% and varies by series. (balinisteanu2024unlockingthegenetic pages 9-11, vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, tang2024gnasmutationssuppress pages 1-2, rymuza2024highlevelof pages 1-2)
  • Syndromic / mosaic genetic context: Postzygotic activating GNAS variants cause McCune–Albright syndrome (MAS), which can include GH excess and pituitary involvement; this is a related mechanism but distinct from most sporadic acromegaly-associated somatotroph tumors. (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic pages 1-2)

Environmental, infectious, and lifestyle risk factors: Not identified in the retrieved evidence set specific to GNAS-driven pituitary adenomas.

2.3 Protective factors

No robust genetic or environmental protective factors specific to this entity were identified in the retrieved evidence set.

2.4 Gene–environment interactions

No specific gene–environment interaction evidence was identified in the retrieved evidence set.

3. Phenotypes

3.1 Core clinical phenotype: GH excess / acromegaly

Somatotroph PitNETs cause acromegaly, classically characterized biochemically by elevated IGF-1 and failure of GH suppression after oral glucose tolerance testing (OGTT). (rymuza2024highlevelof pages 1-2)

HPO suggestions (common in acromegaly; map for knowledge base use): * Elevated insulin-like growth factor 1: HP:0033688 (suggested) * Elevated growth hormone: HP:0011745 (suggested) * Enlarged hands/feet: HP:0001197, HP:0001833 (suggested) * Prognathism: HP:0000303 (suggested) * Headache: HP:0002315 (suggested; pituitary mass effect) * Visual field defect (e.g., bitemporal hemianopia): HP:0000580 (suggested; mass effect)

(These HPO mappings are ontology suggestions; the retrieved evidence directly supports acromegaly/GH excess and tumor behavior rather than listing individual HPO-coded symptoms.) (dillon2026clinicalcharacteristicsassociated pages 1-2, rymuza2024highlevelof pages 1-2)

3.2 Tumor phenotype: size and invasion

Across studies, GNAS-mutant acromegaly tumors are frequently reported to be smaller and possibly less invasive than GNAS-wild-type tumors. (dillon2026clinicalcharacteristicsassociated pages 1-2, tang2024gnasmutationssuppress pages 1-2)

Recent cohort statistic: In a Chinese surgical cohort (n=97), patients with GNAS-mutant tumors had smaller maximum tumor diameters (mean 1.75 ± 0.83 cm vs 2.23 ± 0.89 cm, P=0.008). (balinisteanu2024unlockingthegenetic pages 9-11)

HPO suggestions (tumor invasion/mass effect): * Pituitary adenoma: HP:0007009 (suggested) * Visual field defect: HP:0000580 (suggested) * Headache: HP:0002315 (suggested)

3.3 Histopathology phenotype (tumor subtype associations)

Reviews and clinical series commonly associate GNAS-mutant tumors with densely granulated somatotroph histology and, in some series, mammosomatotroph classification. (balinisteanu2024unlockingthegenetic pages 9-11, dillon2026clinicalcharacteristicsassociated pages 1-2, balinisteanu2024unlockingthegenetic pages 3-4)

4. Genetic / Molecular Information

4.1 Causal gene

  • GNAS (HGNC symbol: GNAS; “GNAS complex locus”) encodes Gsα, the α subunit of a stimulatory heterotrimeric G protein coupling GPCRs to adenylyl cyclase. (torresmoran2023hotspotsofsomatic pages 4-6, torresmoran2023hotspotsofsomatic media 493c647d)

4.2 Pathogenic variants (somatic hotspots)

  • Hotspot residues: R201 and Q227 are recurrently mutated in PitNETs, especially somatotroph tumors. (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic media 804a8a89)
  • Mechanistic consequence: Hotspot variants stabilize Gsα in an active state and inhibit its intrinsic GTPase activity, resulting in constitutive cAMP signaling. (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic media 804a8a89, torresmoran2023hotspotsofsomatic media 493c647d)

Variant examples (from review text): p.R201C, p.R201S are explicitly mentioned as hotspot examples in the PitNET hotspot review. (torresmoran2023hotspotsofsomatic pages 4-6)

Somatic vs germline: The driver context for most GNAS-related pituitary adenomas is somatic tumor mutation; MAS reflects postzygotic mosaic (not inherited) activating variants. (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic pages 1-2)

ACMG/AMP classification & population allele frequency: Not directly retrievable from the current evidence set (ClinVar/gnomAD were not queried within the tool outputs).

4.3 Modifier genes / additional genomic features

A 2024 multi-omics study of somatotroph PitNETs emphasized heterogeneous copy number alteration (CNA) patterns and described recurrent chromosome 11 loss with reduced MEN1 and AIP, and a highly aneuploid subgroup that was largely GNAS-wild-type. (rymuza2024highlevelof pages 1-2)

4.4 Epigenetic information

Not specifically extracted for GNAS-mutant tumors in the current evidence set; however, CNA-associated methylation/transcriptome differences were reported in somatotroph PitNETs at the cohort level. (rymuza2024highlevelof pages 1-2)

5. Environmental Information

No disease-specific environmental, lifestyle, or infectious contributors were identified in the retrieved evidence set for GNAS-driven pituitary adenomas.

6. Mechanism / Pathophysiology

6.1 Canonical pathway: GPCR–Gsα–adenylyl cyclase–cAMP–PKA

A recent hotspot-focused review outlines the normal Gsα cycle (GPCR-triggered GDP→GTP exchange, adenylyl cyclase activation, cAMP production, termination by intrinsic GTPase) and explains that GNAS hotspot variants disable termination, driving persistent signaling. (torresmoran2023hotspotsofsomatic pages 4-6, torresmoran2023hotspotsofsomatic media 493c647d)

Causal chain (mechanistic): 1. Somatic activating GNAS hotspot mutation in somatotroph-lineage pituitary cell (upstream trigger). (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic media 804a8a89) 2. Constitutive activation of adenylyl cyclase → increased cAMP → increased PKA activity and downstream transcriptional programs (e.g., via CREB). (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic media 493c647d) 3. Increased GH transcription and secretion and enhanced somatotroph proliferation → formation of GH-secreting PitNET. (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, torresmoran2023hotspotsofsomatic media 493c647d) 4. Systemic GH/IGF-1 excess → clinical acromegaly. (rymuza2024highlevelof pages 1-2)

Ontology suggestions (GO / pathways): * GO: cAMP-mediated signaling: GO:0019933 (suggested) * GO: adenylate cyclase-activating GPCR signaling: GO:0007189 (suggested) * GO: protein kinase A signaling: GO:0010737 (suggested) * GO: regulation of hormone secretion: GO:0046883 (suggested)

6.2 Invasion biology (recent 2024 development): MEG3–EMT–Wnt/β-catenin

A 2024 experimental study reported that GNAS-mutant GH pituitary adenomas show increased MEG3 (lncRNA) expression and that MEG3 suppresses invasion by inhibiting EMT and Wnt/β-catenin signaling; the authors conclude “GNAS mutations may suppress cell invasion… through the activation of the MEG3/Wnt/β-catenin signaling pathway.” (tang2024gnasmutationssuppress pages 1-2)

Direct abstract support (primary): Tang et al. (2024) states: “Approximately 30%–40% of growth hormone–secreting pituitary adenomas (GHPAs) harbor somatic activating mutations in GNAS…” and describes MEG3-associated suppression of invasion. (tang2024gnasmutationssuppress pages 1-2)

Ontology suggestions: * GO: epithelial to mesenchymal transition: GO:0001837 (suggested) * GO: Wnt signaling pathway: GO:0016055 (suggested)

6.3 Cell types involved (Cell Ontology suggestions)

  • Pituitary somatotroph: CL:0002371 (suggested)
  • Pituitary lactotroph: CL:0002370 (suggested; relevant to mammosomatotroph phenotype)

7. Anatomical Structures Affected

7.1 Organ/tissue

  • Primary site: Anterior pituitary (adenohypophysis) (UBERON suggestion: UBERON:0000007 pituitary gland; adenohypophysis UBERON:0000005).

7.2 Secondary systemic involvement (via hormone excess)

Systemic morbidity is mediated largely by GH/IGF-1 excess (acromegaly), rather than metastatic spread (PitNETs are generally benign). (torresmoran2023hotspotsofsomatic pages 1-2)

8. Temporal Development

8.1 Onset and diagnostic delay

Acromegaly is described as an “insidious” disease in systematic review synthesis, consistent with delayed diagnosis. (dillon2026clinicalcharacteristicsassociated pages 1-2)

A recent cohort reported longer diagnosis delays in GNAS-mutant patients (median 72 vs 36 months) in one series. (balinisteanu2024unlockingthegenetic pages 9-11)

8.2 Course / progression

GNAS-mutant tumors are often described as smaller and less invasive, suggesting a comparatively less aggressive local course in many series, though prognostic utility remains insufficient for clinical decision-making. (dillon2026clinicalcharacteristicsassociated pages 1-2, tang2024gnasmutationssuppress pages 1-2)

9. Inheritance and Population

9.1 Epidemiology

  • Clinically relevant pituitary adenomas overall: ~1/1000 prevalence (review). (torresmoran2023hotspotsofsomatic pages 1-2)
  • GNAS mutation frequency in somatotroph (GH-secreting) PitNETs: commonly ~35–40% in reviews. (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8, tang2024gnasmutationssuppress pages 1-2, rymuza2024highlevelof pages 1-2)

9.2 Population demographics (recent cohort-level observations)

A systematic review found that while some studies report older age or male predominance among GNAS+ tumors, “most did not find this association,” indicating inconsistent demographic correlation. (dillon2026clinicalcharacteristicsassociated pages 1-2)

10. Diagnostics

10.1 Clinical / biochemical

  • IGF-1 elevation and lack of GH suppression on OGTT are used in somatotroph PitNET characterization (study background/definition). (rymuza2024highlevelof pages 1-2)

10.2 Imaging

Pituitary MRI is used to assess tumor size and invasion; in the 2024 mechanistic study, invasiveness was operationalized by MRI-based Knosp grading. (tang2024gnasmutationssuppress pages 1-2)

10.3 Pathology

Somatotroph tumors are classified by granulation patterns (dense vs sparse) and lineage markers (e.g., PIT-1, GH). (rymuza2024highlevelof pages 1-2)

10.4 Molecular testing (real-world implementation)

Hotspot driver mutations “are easily detectable in clinical samples via Sanger or next-generation sequencing (NGS).” (torresmoran2023hotspotsofsomatic pages 1-2)

Implementation note: Routine clinical adoption of GNAS testing varies by center; the systematic review concludes that GNAS status cannot yet be used reliably to guide prognosis and treatment in acromegaly, implying limited decision-impact in current practice. (dillon2026clinicalcharacteristicsassociated pages 1-2)

11. Outcome / Prognosis

GNAS+ somatotroph tumors are more consistently associated with smaller size and possibly less invasiveness, but systematic review synthesis concludes that GNAS mutation status “cannot reliably inform prognosis and treatment… based on findings to date.” (dillon2026clinicalcharacteristicsassociated pages 1-2)

No overall survival statistics specific to GNAS-mutant somatotroph tumors were identified in the retrieved evidence set.

12. Treatment

12.1 Standard-of-care modalities (real-world)

  • Transsphenoidal surgery is a mainstay (noted as treatment context in recent cohorts). (balinisteanu2024unlockingthegenetic pages 9-11, rymuza2024highlevelof pages 1-2)
  • Somatostatin receptor ligands (SRLs) such as octreotide and lanreotide are used preoperatively and/or as medical therapy. (rymuza2024highlevelof pages 1-2)

12.2 Relationship of GNAS status to treatment response (expert synthesis)

  • A systematic review reports greater acute GH suppression after octreotide is “frequently” observed, but long-term biochemical control with SRLs is not consistently associated with GNAS mutation status. (dillon2026clinicalcharacteristicsassociated pages 1-2)
  • A management-focused review notes better response to somatostatin analogues has been reported in some studies, but results are “controversial” across cohorts. (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8)

12.3 MAXO suggestions

  • Transsphenoidal hypophysectomy / pituitary tumor resection: MAXO:0001088 (suggested)
  • Somatostatin analog therapy: MAXO:0000574 (suggested)
  • MRI of pituitary: MAXO:0000910 (suggested; if used for diagnostic action)

(These MAXO terms are suggestions; the retrieved evidence supports these interventions but does not provide MAXO annotations.) (dillon2026clinicalcharacteristicsassociated pages 1-2, rymuza2024highlevelof pages 1-2)

13. Prevention

No primary prevention strategies specific to GNAS-driven pituitary adenoma formation were identified in the retrieved evidence set. Secondary prevention in practice is generally earlier recognition of acromegaly and pituitary mass effects, but no guideline-level screening recommendations were retrieved here.

14. Other Species / Natural Disease

No naturally occurring veterinary analogs specific to GNAS-mutant pituitary adenomas were identified in the retrieved evidence set.

15. Model Organisms

A 2024 mechanistic study used: * GH3 pituitary cell line (rat somatotroph/lactotroph lineage model) with mutant GNAS expression (in vitro) and * a mouse xenograft model to test effects on tumor invasiveness (in vivo). (tang2024gnasmutationssuppress pages 1-2)

Model limitations (inferred from study design): GH3/xenograft systems model invasion biology but do not fully capture human pituitary microenvironment, endocrine feedback loops, or long-term treatment response heterogeneity. (tang2024gnasmutationssuppress pages 1-2)

Visual evidence (figure/table)

A hotspot-variant review includes a table and pathway figure summarizing GNAS hotspots (R201, Q227) and the cAMP pathway in somatotroph cells, supporting the mechanistic chain and hotspot definition. (torresmoran2023hotspotsofsomatic media 804a8a89, torresmoran2023hotspotsofsomatic media 493c647d)

Notes on evidence coverage and gaps

  • The specific label “GNAS-related pituitary adenoma 3” did not appear as a standardized entity name within the retrieved papers; therefore, this report uses genotype+phenotype mapping to GH-lineage PitNETs with somatic activating GNAS variants, supported by reviews, systematic synthesis, and disease-target ontology resources. (OpenTargets Search: pituitary adenoma,acromegaly-GNAS, dillon2026clinicalcharacteristicsassociated pages 1-2, vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8)
  • Some requested elements (e.g., formal MONDO/ICD/MeSH identifiers for the exact label; ClinVar classifications; population allele frequencies from gnomAD; dedicated QoL instruments) were not available in the retrieved evidence set.

References

  1. (OpenTargets Search: pituitary adenoma,acromegaly-GNAS): Open Targets Query (pituitary adenoma,acromegaly-GNAS, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  2. (dillon2026clinicalcharacteristicsassociated pages 1-2): Brendan R. Dillon, Margaret Ruddy, Emily C. McQuade, Shruti N. Shah, Alberta Twi-Yeboah, Benjamin A. Levinson, and Nidhi Agrawal. Clinical characteristics associated with somatic gnas mutations in acromegaly: a systematic review and institutional experience. Frontiers in Endocrinology, Jan 2026. URL: https://doi.org/10.3389/fendo.2026.1736208, doi:10.3389/fendo.2026.1736208. This article has 2 citations.

  3. (vamvoukaki2023pituitarytumorigenesis—implicationsfor pages 6-8): Rodanthi Vamvoukaki, Maria Chrysoulaki, Grigoria Betsi, and Paraskevi Xekouki. Pituitary tumorigenesis—implications for management. Medicina, 59:812, Apr 2023. URL: https://doi.org/10.3390/medicina59040812, doi:10.3390/medicina59040812. This article has 15 citations.

  4. (torresmoran2023hotspotsofsomatic pages 1-2): Mariana Torres-Morán, Alexa L. Franco-Álvarez, Rosa G. Rebollar-Vega, and Laura C. Hernández-Ramírez. Hotspots of somatic genetic variation in pituitary neuroendocrine tumors. Cancers, 15:5685, Dec 2023. URL: https://doi.org/10.3390/cancers15235685, doi:10.3390/cancers15235685. This article has 9 citations.

  5. (torresmoran2023hotspotsofsomatic pages 4-6): Mariana Torres-Morán, Alexa L. Franco-Álvarez, Rosa G. Rebollar-Vega, and Laura C. Hernández-Ramírez. Hotspots of somatic genetic variation in pituitary neuroendocrine tumors. Cancers, 15:5685, Dec 2023. URL: https://doi.org/10.3390/cancers15235685, doi:10.3390/cancers15235685. This article has 9 citations.

  6. (torresmoran2023hotspotsofsomatic media 804a8a89): Mariana Torres-Morán, Alexa L. Franco-Álvarez, Rosa G. Rebollar-Vega, and Laura C. Hernández-Ramírez. Hotspots of somatic genetic variation in pituitary neuroendocrine tumors. Cancers, 15:5685, Dec 2023. URL: https://doi.org/10.3390/cancers15235685, doi:10.3390/cancers15235685. This article has 9 citations.

  7. (tang2024gnasmutationssuppress pages 1-2): Chao Tang, Chunyu Zhong, Junhao Zhu, Feng Yuan, Jin Yang, Yong Xu, and Chiyuan Ma. Gnas mutations suppress cell invasion by activating meg3 in growth hormone–secreting pituitary adenoma. Oncology Research, 32:1079-1091, May 2024. URL: https://doi.org/10.32604/or.2024.046007, doi:10.32604/or.2024.046007. This article has 5 citations and is from a peer-reviewed journal.

  8. (rymuza2024highlevelof pages 1-2): Julia Rymuza, Paulina Kober, Maria Maksymowicz, Aleksandra Nyc, Beata J. Mossakowska, Renata Woroniecka, Natalia Maławska, Beata Grygalewicz, Szymon Baluszek, Grzegorz Zieliński, Jacek Kunicki, and Mateusz Bujko. High level of aneuploidy and recurrent loss of chromosome 11 as relevant features of somatotroph pituitary tumors. Journal of Translational Medicine, Nov 2024. URL: https://doi.org/10.1186/s12967-024-05736-0, doi:10.1186/s12967-024-05736-0. This article has 8 citations and is from a peer-reviewed journal.

  9. (balinisteanu2024unlockingthegenetic pages 9-11): Ioana Balinisteanu, Lavinia Caba, Andreea Florea, Roxana Popescu, Laura Florea, Maria-Christina Ungureanu, Letitia Leustean, Eusebiu Vlad Gorduza, and Cristina Preda. Unlocking the genetic secrets of acromegaly: exploring the role of genetics in a rare disorder. Current Issues in Molecular Biology, 46:9093-9121, Aug 2024. URL: https://doi.org/10.3390/cimb46080538, doi:10.3390/cimb46080538. This article has 8 citations.

  10. (balinisteanu2024unlockingthegenetic pages 3-4): Ioana Balinisteanu, Lavinia Caba, Andreea Florea, Roxana Popescu, Laura Florea, Maria-Christina Ungureanu, Letitia Leustean, Eusebiu Vlad Gorduza, and Cristina Preda. Unlocking the genetic secrets of acromegaly: exploring the role of genetics in a rare disorder. Current Issues in Molecular Biology, 46:9093-9121, Aug 2024. URL: https://doi.org/10.3390/cimb46080538, doi:10.3390/cimb46080538. This article has 8 citations.

  11. (torresmoran2023hotspotsofsomatic media 493c647d): Mariana Torres-Morán, Alexa L. Franco-Álvarez, Rosa G. Rebollar-Vega, and Laura C. Hernández-Ramírez. Hotspots of somatic genetic variation in pituitary neuroendocrine tumors. Cancers, 15:5685, Dec 2023. URL: https://doi.org/10.3390/cancers15235685, doi:10.3390/cancers15235685. This article has 9 citations.

Artifacts